Cyteir Therapeutics, Inc. (CYT)
Cyteir Therapeutics, Inc.
128 Spring Street
Building A Suite 510
Lexington, MA 02421
United States
857 285 4140
https://cyteir.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 40
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Joseph S. Zakrzewski | Independent Investor & Independent Chairman | 80.8k | N/D | 1962 |
| Dr. Markus F. Renschler M.D. | Pres, CEO & Director | 731.36k | N/D | 1961 |
| Mr. Timothy Romberger | Independent Director | 26.67k | N/D | 1972 |
| Dr. Paul Secrist Ph.D. | Chief Scientific Officer | 535.02k | N/D | 1967 |
| Mr. Andrew W. Gengos | Chief Bus. Officer & Sec. | 536.9k | N/D | 1964 |
| Dr. Kevin Mills Ph.D. | Co-Founder | N/D | N/D | N/D |
| Mr. David G. Gaiero | VP of Fin. | N/D | N/D | 1979 |
| Ms. Lisa A. Hayes | VP of Investor Relations & Corp. Communications | N/D | N/D | N/D |
| Mr. Adam M. Veness Esq. | Gen. Counsel | N/D | N/D | 1986 |
| Ms. Gale Cohen | VP of HR | N/D | N/D | N/D |
Descripción
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts.
Gestión corporativa
La calificación ISS Governance QuickScore de Cyteir Therapeutics, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
